TAXUS Set For April 2004 Approval Based On Tentative Cypher Timeline
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will not be granted expedited review for its Taxus paclitaxel-eluting stent after Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent is approved in the U.S., based on the premise that fast-track PMAs should address an unmet clinical need